Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK interactions between ivacaftor and CYP3A4 inhibitors in cystic fibrosis and healthy subjects
2016-001440-18Phase 4Active
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: RAUC of ivacaftor with CYP3A inhibitors vs control. Started Jan 2018; status: active.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2016-001440-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001440-18.